Étiquette : pharmacologie

Psychedelics in the treatment of unipolar mood disorders : a systematic review, James J.H. Rucker et al., 2016

Psychedelics in the treatment of unipolar mood disorders : a systematic review James J.H. Rucker, Luke A. Jelen, Sarah Flynn, Kyle D. Frowde and Allan H. Young Journal of Psychopharmacology, 2016, 1-10 DOI: 10.1177/0269881116679368 Abstract Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used extensively in the treatment of mood disorders, and other psychiatric conditions, before their prohibition in the [...]

Lire la suite

Introduction, 24e Journées du RESPADD “Usages thérapeutiques des cannabinoïdes”, session du GRECC, dr Christian Sueur, 26 juin 2019

Introduction, 24e Journées du RESPADD "Usages thérapeutiques des cannabinoïdes", Session du GRECC, Docteur Christian Sueur, 26 juin 2019, Paris   Bonjour Bienvenu à toutes et à tous Merci d’être venus aussi nombreux à ce premier colloque co-organisé par le GRECC et le RESPADD sur le thème du Cannabis Thérapeutique, ou, de façon « dépassionnée », sur les Usages Cliniques des Cannabinoïdes. Je veux tout d’abord remercier Nicolas Bonnet, Anne Borgne et le RESPADD de nous avoir invité à leur colloque annuel, de nous avoir donné offert cette première demie journée, et d’avoir invité de nombreux intervenants que nous avons proposés pour ces 2 jours de rencontres cannabiques.   Le GRECC (Groupe de [...]

Lire la suite

Psychedelic Drugs in Biomedicine, Evan J. KYZAR, 2017

Psychedelic Drugs in Biomedicine Evan J. KYZAR, Charles D. NICHOLS, Paul R. GAINETDINOV, David E. NICHOLS, Allan V. KALUEFF  Trends in Pharmacological Sciences, 2017, 38, (1), 992-1005 https://doi.org/10.1016/j.tips.2017.08.003 Trends Psychedelic drugs profoundly alter human behavior, acting primarily via agonism at the 5-HT2A receptor in the brain. Research into the mechanisms of psychedelic drugs is experiencing a renaissance after years of stagnation. Animal models show that psychedelic drugs alter a number of crucial molecular mechanisms. Psychedelic drugs cause widespread changes in cognition and brain connectivity. Recent pilot studies show LSD and psilocybin are effective in treating psychiatric disorders and possibly other illnesses. Psychedelic biomedicine is rapidly emerging as an important area [...]

Lire la suite

L’expérimentation du cannabis thérapeutique officiellement autorisée en France, Le Monde avec AFP, Publié le 11 juillet 2019

L’expérimentation du cannabis thérapeutique officiellement autorisée en France Une décision de l’agence française du médicament ouvre la voie à un test en situation réelle réservé aux patients en impasse thérapeutique. Le Monde avec AFP Publié le 11 juillet 2019 à 11h20 - Mis à jour le 11 juillet 2019 à 11h26   Un plant de cannabis thérapeutique, Israël, le 24 janvier 2019. Amir Cohen / REUTERS C’est une nouvelle étape vers l’expérimentation du cannabis thérapeutique en France : l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) a validé jeudi 11 juillet le cadre proposé fin juin par un groupe [...]

Lire la suite

N-Arachidonoyl Dopamine : A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities, Urszula Grabiec and Faramarz Dehghan, 2017

N-Arachidonoyl Dopamine : A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities Urszula Grabiec and Faramarz Dehghani Cannabis and Cannabinoid Research, 2017, 2, (1), 183-196 DOI: 10.1089/can.2017.0015   Abstract N-arachidonoyl dopamine (NADA) is a member of the family of endocannabinoids to which several other N-acyldopamines belong as well. Their activity is mediated through various targets that include cannabinoid receptors or transient receptor potential vanilloid (TRPV)1. Synthesis and degradation of NADA are not yet fully understood. Nonetheless, there is evidence that NADA plays an important role in nociception and inflammation in the central and peripheral nervous system. The TRPV1 receptor, for which NADA is a [...]

Lire la suite

Lysergic acid diethylamide : a drug of ‘use’?, Saibal Das et al., 2016

Lysergic acid diethylamide : a drug of ‘use’ ? Saibal Das, Preeti Barnwal, Anand Ramasamy, Sumalya Sen and Somnath Mondal Therapeutic Advances in Psychopharmacology, 2016, Vol. 6, (3), 214–228 DOI: 10.1177/2045125316640440   Abstract : Lysergic acid diethylamide (LSD), described as a classical hallucinogen, began its journey from the middle of the last century following an accidental discovery. Since then, it was used as a popular and notorious substance of abuse in various parts of the world. Its beneficial role as an adjunct to psychotherapy was much unknown, until some ‘benevolent’ experiments were carried out over time to explore some of its potential uses. But, many [...]

Lire la suite

Prevalence and Correlates of Cannabis Use in Outpatients with Serious Mental, Jordan Skalisky et al., 2017Illness Receiving Treatment for Alcohol Use Disorders, Jordan Skalisky et al., 2017

Prevalence and Correlates of Cannabis Use in Outpatients with Serious Mental Illness Receiving Treatment for Alcohol Use Disorders Jordan Skalisky, Emily Leickly, Oladunni Oluwoye, Sterling M. McPherson, Debra Srebnik, John M. Roll, Richard K. Ries, and Michael G. McDonell Cannabis and Cannabinoid Research, 2017, 2, (1), 133-138 DOI: 10.1089/can.2017.0006   Abstract Introduction : People with serious mental illness (SMI) use cannabis more than any other illicit drug. Cannabis use is associated with increased psychotic symptoms and is highly comorbid with alcohol use disorders (AUDs). Despite the national trend toward decriminalization, little is known about the prevalence, correlates, and impact of cannabis use on those with SMI [...]

Lire la suite

Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults, David L. Arndt and Harriet de Wit, 2017

Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults David L. Arndt and Harriet de Wit Cannabis and Cannabinoid Research, 2017, 2, (1), 105-113 DOI: 10.1089/can.2017.0014 Abstract Introduction : Cannabidiol (CBD) is a nonpsychoactive constituent of whole plant cannabis that has been reported to reduce anxiety-like behaviors in both pre-clinical and human laboratory studies. Yet, no controlled clinical studies have demonstrated its ability to reduce negative mood or dampen responses to negative emotional stimuli in humans. The objective of this study was to investigate the effects of CBD on responses to negative emotional stimuli, as a model for its potential anxiety-reducing effects. Materials and [...]

Lire la suite

A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans, Gerhard Nahler et al., 2017

A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans Gerhard Nahler, Franjo Grotenhermen, Antonio Waldo Zuardi, and Jose´ A.S. Crippa3 Cannabis and Cannabinoid Research, 2017, 2, 1, 81-86 DOI: 10.1089/can.2017.0009 Abstract Cannabidiol (CBD), a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic properties. Under acidic conditions, CBD can be transformed to delta9 tetrahydro-cannabinol (THC) and other cannabinoids. It has been argued that this may occur also after oral administration in humans. However, the experimental conversion of CBD to THC and delta8-THC in simulated gastric fluid (SGF) is a highly artificial approach that deviates [...]

Lire la suite

Predicting Responses to Psychedelics : A Prospective Study, Eline C. H. M. Haijen et al., 2018

Predicting Responses to Psychedelics : A Prospective Study Eline C. H. M. Haijen, Mendel Kaelen, Leor Roseman, Christopher Timmermann, Hannes Kettner, Suzanne Russ, David Nutt, Richard E. Daws, Adam D. G. Hampshire, Romy Lorenz  and Robin L. Carhart-Harris Frontiers in Pharmacology, 2018 doi: 10.3389/fphar.2018.00897   Abstract Responses to psychedelics are notoriously difficult to predict, yet significant work is currently underway to assess their therapeutic potential and the level of interest in psychedelics among the general public appears to be increasing. We aimed to collect prospective data in order to improve our ability to predict acute- and longer-term responses to psychedelics. Individuals who planned to take a [...]

Lire la suite